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Abstract:  
Background. Non-inferiority trials are increasingly used to evaluate new treatments expected 
to have secondary advantages over standard of care, but similar efficacy on the primary 
outcome. When designing a non-inferiority trial with a binary primary outcome, the choice of 
effect measure for the non-inferiority margin (e.g. risk ratio or risk difference) has an 
important effect on sample size calculations; furthermore, if the control event risk observed is 
markedly different from that assumed, the trial can quickly lose power or the results become 
difficult to interpret.  
Methods. We propose a new way of designing non-inferiority trials to overcome the issues 
raised by unexpected control event risks. Our proposal involves specifying a “non-inferiority 
frontier”, i.e. a curve defining the most appropriate non-inferiority margin for each possible 
value of control event risk. We propose a fixed arcsine difference frontier, using the power-
stabilising transformation for binary outcomes. We propose and compare three ways of 
designing a trial using this frontier: testing and reporting on the arcsine scale; testing on the 
arcsine scale but reporting on the risk difference or risk ratio scale; and modifying the margin 
on the risk difference or risk ratio scale after observing the control event risk according to the 
power-stabilising frontier.  
Results. Testing and reporting on the arcsine scale leads to results which are challenging to 
interpret clinically. For small values of control event risk, testing on the arcsine scale and 
reporting results on the risk difference scale produces confidence intervals at a higher level 
than the nominal one or non-inferiority margins that are slightly smaller than those back-
calculated from the power-stabilising frontier alone. However, working on the arcsine scale 
generally requires a larger sample size compared to the risk difference scale. Therefore, 
working on the risk difference scale, modifying the margin after observing the control event 
risk, might be preferable, as it requires a smaller sample size. However, this approach tends 
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to slightly inflate type I error rate; a solution is to use a lower significance level for testing, 
although this modestly reduces power.  
When working on the risk ratio scale instead, the same approach based on the modification of 
the margin leads to power levels above the nominal one, maintaining type I error under 
control.  
Conclusions. Our proposed methods of designing non-inferiority trials using power-
stabilising non-inferiority frontiers make trial design more resilient to unexpected values of 
the control event risk, at the only cost of requiring larger sample sizes when the goal is to 
report results on the risk difference scale. 
1. Introduction 
Often a new treatment is expected not to have greater efficacy than the standard treatment, 
but to provide advantages in terms of costs, side-effects or acceptability. Here, a non-
inferiority trial1 can test whether the new treatment’s efficacy is not unacceptably lower than 
standard treatment, and also where relevant guarantee that a minimum acceptable treatment 
effect relative to placebo is preserved, whilst providing sufficient evidence of superiority on 
secondary outcomes to support its use. Non-inferiority designs have been increasingly used in 
recent years2. 
  
A critical design choice is the non-inferiority margin, which is the largest acceptable loss of 
efficacy3. Considerations regarding margin choice depend on the type of primary outcome. 
We focus here on binary outcomes, for which either absolute4 (risk difference) or relative5 
(risk ratio) margins can be defined. For example, the Food and Drug Administration 
guidelines6 suggest that for licensing trials the results from placebo-controlled trials 
evaluating the standard treatment might inform margin choice, using the lower bound of the 
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confidence interval for the estimated effect vs placebo, most often using the absolute scale. In 
other situations, the goal might be to preserve a certain proportion of the effect of the 
standard relative to placebo, which can be formulated as either an absolute or relative margin. 
  
In both cases, the expected control arm (standard treatment) event risk plays a very important 
role in the choice of the non-inferiority margin7. However, at trial completion, the actual 
control event risk can differ considerably from the expected one. This can occur when prior 
information was not correct, for example when standard of care has improved over years8 or 
because a slightly different sub-population was recruited4 or because additional aspects of 
care (or a Hawthorne effect) influence outcomes in the control group. This can have serious 
consequences on the power, and hence the interpretation, of the trial, particularly when the 
expected control event risk is very large (e.g. >90%) or small (<10%): the latter is common in 
non-inferiority trials where existing treatments are often highly effective precluding 
demonstrating superiority of a new treatment on the primary endpoint.  
 
For example, for control risk <0.5, the sample size needed to achieve 90% power under a 5% 
non-inferiority margin on the risk difference scale (one-sided alpha=2.5%) increases with the 
control event risk (Figure (a) in the additional material online); hence, if the control event risk 
is larger than anticipated, this reduces the power of the trial to demonstrate non-inferiority 
(Figure (b)). The opposite occurs when working on the risk ratio scale, so that a lower than 
expected control event risk reduces power. We discuss a specific example illustrating this 
below (the OVIVA trial9). Furthermore, higher power than designed may not actually aid 
interpretation. For example, Mauri and D’Agostino10 discuss the ISAR-safe11 non-inferiority 
trial, where the observed control event risk was much lower than originally expected. The 
results provided strong evidence of non-inferiority based on the pre-specified non-inferiority 
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margin as a risk difference, but they were also consistent with a three-fold increase in risk, 
and so the authors did not conclude non-inferiority.  
 
Here we propose a new method of designing non-inferiority trials, which protects against a 
lower or higher than expected control event risk, preserving power and interpretability of 
results.  
2. The non-inferiority frontier 
 
Assume we want to test whether a new treatment T1 is non-inferior to the standard treatment 
T0. The primary (binary) outcome is an unfavourable event, e.g. death or relapse within one 
year from randomisation. Let:  
• ,  be the true incidences in the experimental and control groups respectively 
•  ,  be the expected incidences assumed in the sample size calculation. Usually 
 =  but occasionally4 studies are designed with  <  or  > . 
• 	 be the largest acceptable incidence in the experimental group if the control group 
incidence is . In a trial with an unfavourable outcome, 	 > .  
• 
 be the non-inferiority margin, defined as 
 = 	 −  if the risk difference scale 
is used, and 
 = log	(	/) if the (log-)risk ratio scale is used. 
• ,  be the sample sizes, with allocation ratio  = /.	
 
Several recommendations have been given regarding choice of the most appropriate non-
inferiority margin3,6, involving both clinical and statistical considerations. Whilst sample size 
calculations allow for stochastic variation between the true control event risk  and its final 
observed estimate , they do not allow for substantial misjudgment in the envisaged truth. 
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We therefore argue that it is insufficient to define non-inferiority in terms of a single margin 

; it is instead preferable, at the design stage, to define a curve associating a specific 
margin	
	to each possible value of control event risk . We call this the Non-Inferiority 
Frontier.  
2.1. Risk Difference vs. Risk Ratio 
The standard design, assuming a single non-inferiority margin 
 irrespective of , 
corresponds to a fixed risk difference or fixed risk ratio frontier. These frontiers are shown in 
Figure 1. The region underneath the golden line is the non-inferiority region assuming a fixed 
risk difference frontier; whatever the control event risk, the new treatment is judged non-
inferior if  −  < 0.05. Similarly, the region below the blue line is the non-inferiority 
region assuming a constant risk ratio frontier. 
  
The choice of frontier is important even when the expected control event risk is correct, i.e. 
 = . As shown by Figure (a) and (b) in the additional material, power and sample size 
calculations using different analysis scales give very different answers even when the 
assumed 	 and  are the same.  
2.2. The power-stabilising non-inferiority frontier 
We propose a third choice of frontier, the fixed arcsine difference12,13 frontier, i.e. constant 
asin 	! −	asin !	. Although the arcsine difference is more difficult to interpret 
than other measures, its great advantage is that its asymptotic variance is independent of . 
Hence, when using a fixed arcsine difference frontier, the sample size and power calculations 
are approximately unaffected by  − . We therefore call this the Power-Stabilising Non-
Inferiority Frontier, represented by the dark green line in Figure 1. 
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2.3. Choosing the non-inferiority frontier 
The most appropriate non-inferiority frontier must be chosen using clinical, as well as 
statistical, arguments. If the investigators’ only interest lies in the single binary efficacy 
outcome, an increase in event risk from 5% to 10% can be considered as undesirable as an 
increase from 45% to 50%; in both, the experimental treatment leads to 50 more events per 
1000 patients and a fixed risk difference frontier might be appropriate. However, many 
investigators would feel that the former increase is more important than the latter. This could 
be justified by arguing that a relative effect measure is more likely to be transportable to other 
outcomes.  In this case, as the control event risk increases, we might tolerate a larger absolute 
increase in intervention event risk. However, as shown in Figure (a), with the risk ratio 
frontier the maximum tolerable absolute difference quickly becomes very large if the control 
event risk was badly underestimated. The power-stabilising frontier is a good compromise.  
As an example, the OVIVA9 trial aimed to determine whether oral antibiotics were non-
inferior to intravenous antibiotics to cure bone and joint infections. Intravenous antibiotics 
were the standard based on historical precedent, not evidence. Based on pilot data from one 
tertiary referral centre, researchers expected a low control event risk of treatment failure 
( = 5%); given this, they were happy to tolerate up to a 10% event risk for the 
experimental treatment, because of its substantial advantages (e.g reduced line complications, 
earlier hospital discharge), i.e. a 5% absolute margin. However, the observed pooled event 
risk across 29 centres of varying sizes was much higher ( = 12.5%); assuming this 
reflected the control group risk, they were happy to tolerate an experimental event risk larger 
than implied by a fixed risk difference frontier (	 = 17.5%). As the risk ratio increases 
with control risk, a fixed risk ratio frontier (	 = 25%) was an alternative in this case. 
However, the investigators decided that the maximum tolerable experimental event risk given 
 = 12.5% wa&		 = 20%, which is close to the arcsine frontier (	 = 19.5%).  
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Another aspect to consider, when choosing the frontier, is that sample size calculations give 
very different answers when working on different scales. In an example trial with one-sided 
α=2.5%, power=90%,  = 5% and 	 = 10% , the sample size to show non-inferiority on 
the arcsine scale (568 patients/group) is larger than on the risk difference scale (400 
patients/group; 5% absolute margin); hence, choosing the arcsine frontier may require up to 
40% more patients. However, the sample size required to show non-inferiority on the risk 
ratio scale is larger still (832 patients/group; 2-fold relative risk margin).  
3. Implementation 
In a standard non-inferiority trial, results can be interpreted against fixed risk difference or 
risk ratio frontiers. There are several ways we could instead design a trial under the power-
stabilising frontier. We introduce them here and provide an illustrative analysis example in 
Appendix B.  
3.1. Test and report on the arcsine scale 
The simplest solution is to design the trial pre-specifying the non-inferiority margin on the 
arcsine difference scale; it is then sufficient to test non-inferiority at this fixed margin and 
report a point estimate and confidence interval on the arcsine scale, regardless of the final 
observed control event risk. However, such results are not easily interpretable and are 
unlikely to be clinically acceptable.  
3.2. Test on the arcsine scale, report on the risk difference scale 
A second possibility is to perform the test on the arcsine scale, but report results on the risk 
difference (or risk ratio) scale. The problem here is that the test statistic may not correspond 
to the relationship of the margin to the confidence interval. We propose two ways to resolve 
this, and we present them for the risk difference scale, although they could be easily adapted 
to the risk ratio scale; given an estimated arcsine difference ()*  with associated standard error 
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+,-, a fixed non-inferiority margin on the arcsine difference scale 
,- and an estimated risk 
difference ./*  with standard error +01:  
(i) Back calculation of margin.  
1) Calculate the Z statistic for the arcsine scale test:  
2,- = ()
* − 
,-
+,-  
2) Calculate for what non-inferiority margin 
01 we get the same Z statistic when testing 
on the risk difference scale: 

01 = ./* − 2,- ∗ +01 
3) Report the confidence interval on the risk difference scale and p-value of the test for 
non-inferiority at margin 
01: 
4 = 56(2,-)					78(1 − 9) = (./* − :6; ∗ +01	;	./* + :6; ∗ +01) 
 
(ii) Back calculation of significance level and modification of margin.  
1) Calculate the non-inferiority margin 
01∗  on the risk difference scale corresponding to 

,- on the arcsine scale for the observed value of control risk : 
        
01∗ = &>(?&>( ) + ?&>( 	) − ?&>( ))@ −  
2) Calculate the Z statistic 201 for the test on the risk difference scale: 
201 = ./
* − 
01∗
+01  
3) Calculate at what significance level α∗ the test using 201 would be equivalent to a α-
level test using 2,-: 
:6;∗ = :6; 2012,-  
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4) Report (1 − α∗)	confidence interval on the risk difference scale and p-value of the test 
for non-inferiority at margin 
01∗ : 
4 = 56(2,-)					78(1 − α∗) = (./* − :(6B∗) ∗ +01 	; 	./* + :(6B∗) ∗ +01) 
Both approaches are potentially valid; when  < 50%, the adjustment is generally small 
and, most notably, confidence levels reported are larger than the nominal (1 − α). One 
difficulty with this approach is that sample size might be impractically large, particularly for 
small values of control event risk, when the goal is to report on the risk difference scale, for 
the reasons discussed in Section 2.3. Conversely, since sample size required to prove non-
inferiority on the risk ratio scale is larger than on the arcsine scale, the non-inferiority margin 

00 or the significance level α∗ may be unacceptably large when the goal is to report on the 
risk ratio scale.  
3.3. “Conditionally modify margin”: modify non-inferiority margin after 
observing control group event risk 
Our favoured proposal is to design the trial using a standard risk difference or risk ratio 
margin 
 and then modify the margin to 
∗ only if the observed event risk 	differs by more 
than a certain threshold C from the expected . Specifically: 
• At trial completion we observe ; 
• If | − | > C (risk difference scale) or |log	(/)| > C (risk ratio scale), then: 
o Find 	∗  that solves asin EF	∗ G −	asin !	 = 	asin 	! 	−
asin !; 
o Modify non-inferiority margin to 
∗ = 	∗ −  (risk difference) or 
∗ =
log	(HI∗J ) (risk ratio); 
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o Test non-inferiority at margin 
∗; 
• Otherwise do not modify margin and test non-inferiority at 
. 
This approach, while preserving the simplicity in interpreting non-inferiority against risk 
differences or risk ratios, potentially helps preserve power and interpretability when the true 
control event risk is badly misjudged by modifying 
 according to the power-stabilising 
frontier. Differently from the method in Section 3.2(ii), the margin is only modified when the 
observed control risk differs substantially from its expectation. However, since the margin is 
modified in a data-dependent way, the method is potentially prone to inflation of type I error. 
We explore this next. 
3.4. Type I error and power of the “conditionally modify margin” method  
We simulate 100000 datasets for a range of designs and true incidences, starting from a base-
case scenario and then investigating alternatives, changing simulation parameters one-by-one 
(Table 1), appropriately calculating sample size from the design parameters in Table 1 and 
the formulae in the additional material. Since sample size calculations give very different 
answers when using risk ratio or risk difference, we generate different datasets for the two 
effect measures. 
 
Type I Error.  
We consider 40 data-generating mechanisms for each scenario, with  ranging between 
0.5% and 20%, and  derived under the non-inferiority null from the arcsine rule: 
asin(√) −	asin !	 = 	asin 	! 	− asin !. 
This is the appropriate data-generating mechanism for evaluating type I error assuming the 
power-stabilising frontier holds. We compare four different analysis methods: 
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1) Do not modify margin: simply test non-inferiority with margin 
 on the risk 
difference/ratio scale; 
2) Modify margin, with C = 5% for risk difference or log(2) for log risk ratio. 
3) Modify margin, with C = 2.5% for risk difference or log(1.5) for log risk ratio. 
4) Modify margin, with C = 1.25% for risk difference or log(1.25) for log risk ratio. 
Base-case. Figure 2 shows the results of these simulations, designing and analysing the data 
on a risk difference (left) or risk ratio (right) scale. Given our chosen non-inferiority frontier, 
“do not modify margin” leads to inflated type I error rate if the control event risk is lower or 
higher than expected using the risk difference or risk ratio respectively. The three 
“conditionally modify margin” procedures are identical to “do not modify margin” in a small 
region around the expected control event risk; the width of this region is directly proportional 
to the magnitude of C. For  >10%, the margin is almost always modified (Figure (c) in 
additional material), and the “conditionally modify margin” procedures have the same level 
of type I error. Using the risk ratio, this level is below the nominal 2.5%, while with the risk 
difference it is just above 3.5%.  
 
Comparing the strategies with different	C, the procedure using the smallest threshold seems 
preferable irrespective of the scale used. In particular, when using risk ratios, it leads to a 
type I error always below 2.5%, while with risk difference the rate remains slightly inflated at 
about 4% in some areas, particularly with low incidences.  
 
Other data-generating mechanisms. Figure 3 shows the results for the alternative scenarios, 
using procedure 4 only, i.e. “conditionally modify margin” with the smallest threshold (other 
procedures in Figures (d)-(e) in additional online material). Allocation ratio (alternatives 5 
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and 6) has a greater impact than other factors, because with more patients allocated to 
control, the estimated risk is affected by less error. However, in general, conclusions are not 
altered substantially. 
 
Power.  
We again vary  between 0.5% and 20%, but this time under the non-inferiority alternative 
with  = . 
Base-Case. Under “do not modify margin”, power is substantially reduced if  is higher 
(risk difference) or lower (risk ratio) than expected (Figure 2). Using risk ratio, power of any 
of the “conditionally modify margin” methods is always either above the nominal 90% or 
above the power of the “do not modify margin” procedure. The only exception is with  
lower than expected when using risk difference; nevertheless, power remains close to 80% 
even in this scenario. Interestingly, the procedure with the smallest threshold is the only one 
not achieving the nominal power when the control event risk is correct, possibly because the 
margin is at times modified even when risk differs from the expected only because of random 
variation.  
 
Alternatives. Figure 3 shows the results under the alternative scenarios using procedure 4. 
The greatest difference from the base-case configuration is in the scenario where the 
experimental treatment has higher efficacy than the control (Alternative 2), particularly for 
small values of 	and	. This is probably because the arcsine transformation is designed to 
stabilize power under the assumption that  = .  
 
Summary. Under the assumption that a power-stabilising frontier holds, procedure 4, i.e. 
“conditionally modify margin” with a threshold C = 1.25% on the risk difference scale or C = 
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1.25 on the risk ratio scale, is the best procedure. Power is higher than the “do not modify 
margin” procedure in almost all scenarios, and type I error is inflated only with the risk 
difference scale. We next explore two ways to control type I error in this case. 
3.5. Controlling type I error rate 
(i) Smaller fixed 9. The simplest way of controlling type I error is to widen the confidence 
intervals using a smaller significance level 9 than the nominal 2.5% (for a one-sided test). 
We investigate this approach by repeating the base-case simulations for the risk difference, 
using different significance levels with procedure (4), the smallest threshold for margin 
modification. 
 
Type I error is always below or around the nominal 2.5% level when using 9 = 1% (Figure 
4); this leads to a further loss in power of around 8-9% compared to the “do not modify 
margin” method. In general, conclusions depend on the relation between expected and 
observed control event risk: 
•  < : the “conditionally modify margin” procedure with 9 =1% is the only one 
with type I error within 2.5%; 
•  = : the original sample size calculation was correct, and hence the “do not 
modify margin” procedure performs well, while the “conditionally modify margin” 
procedure with smaller 9 loses ~10-15% power; 
•  > : the “do not modify margin” procedure quickly loses power, while all the 
“conditionally modify margin” procedures are quite stable and have correct type I 
error.  
 (ii) Choose 9 given control risk. Whilst one might simply recommend the “conditionally 
modify margin” procedure with 9 = 1%, this approach may be unnecessarily conservative 
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for control event risks where larger 9 still leads to good type I error. Hence, another approach 
could be to choose 9 after observing the control event risk, using the largest 9 leading to 
acceptable type I error for that specific value of the control event risk. This can be estimated 
from simulations with the desired design parameters analogous to Figure 4. However, since 9 
is chosen in a data-dependent way, this procedure is not guaranteed to preserve type I error. 
Nevertheless estimating the type I error from the previous simulations shows the inflation is 
at most modest (Figure 5), and hence this approach could be considered acceptable in 
practice, although it still leads to a 5-10% loss in power. 
A simple way to prevent the additional loss of power is to design the trial using either the 
smaller fixed  9 with method (i) or 9 at 	=	 with method (ii). 
4. Discussion 
We have addressed the challenge of designing a non-inferiority trial that preserves power and 
interpretability of results even when the expected control event risk is badly misjudged. 
Whilst statistically one could argue that sample size re-estimation based on interim analysis, 
updating the control group event risk and maintaining the original non-inferiority margin, 
solves this problem, in practice substantial increases in sample size are typically not 
acceptable to funders and may also be challenging for recruitment. Additionally, we argue 
that keeping the margin fixed may not be the optimal choice for the interpretation of results. 
Therefore alternative statistically principled methods are needed.  
We have proposed three methods based on the definition of a non-inferiority frontier. 
Recently, Hanscom et al.14 proposed using baseline or post-randomisation data to re-estimate 
the non-inferiority margin where this is based on preserving a fraction of the control group 
effect. Our methods are an alternative that can be pre-specified at the trial design stage.  
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4.1. Extensions 
We have considered only binary outcomes, with risk differences and risk ratios as effect 
measures. Our approach could easily incorporate other effect measures, such as odds ratios or 
averted infection ratios15, either to define an alternative non-inferiority frontier, or as the 
basis of a “conditionally modify margin” procedure assuming the power-stabilising frontier. 
Similar considerations could be extended to time-to-event outcomes. Again, a non-inferiority 
frontier could be chosen for absolute differences (e.g. Kaplan-Meier estimates of proportion 
after a certain time) or relative differences (e.g. hazard ratio).  
 
Non-inferiority trials can have continuous outcomes, for example, the Early Treatment 
Diabetic Retinopathy Study score (number of letters a patient can read off a chart from a 
certain distance) in the CLARITY trial16. The investigators used an absolute non-inferiority 
margin of 5 letters, corresponding to a constant difference non-inferiority frontier. This is 
appropriate if the margin is independent of the control group mean. Otherwise, if the 
minimum acceptable number of letters depended on the control group mean, a relative 
difference, e.g. the ratio of the scores, might be used. However, an important difference 
compared to binary outcomes is that the sample size (and hence power) calculations for trials 
with continuous outcomes are independent of the expected control group mean when the 
variance is not associated with the mean. Hence, power is naturally preserved when assuming 
a fixed difference frontier.  
Future work could investigate how to choose the modification threshold C optimally when 
using the “conditionally modify margin” method. 
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4.2. Recommendations  
Given our results, researchers designing non-inferiority trials with a binary or time-to-event 
outcome should carefully consider the following: 
1. The scale on which the non-inferiority comparison is made should be pre-specified in 
the trial protocol, as it substantially affects trial power (and hence sample size); 
2. It is not obvious that the non-inferiority margin should be held fixed (on either risk 
difference or risk ratio scale) when  differs from the expected . Keeping it fixed 
could have implications in terms of power and interpretation, and these need to be 
considered carefully; 
3. A trial design should explicitly pre-specify a “non-inferiority frontier”, i.e. a curve 
indicating the tolerable non-inferiority margin for each value of the control event risk. 
This might be as simple as stating that the non-inferiority margin is fixed on the 
chosen scale; 
4. One choice of non-inferiority frontier is based on the arcsine transformation. 
Although difficult to interpret per-se, this has the advantage of being the power-
stabilising frontier for binomially distributed data;  
5. One approach is to test on the arcsine scale and report results on the risk difference 
scale. However, this generally requires larger sample sizes. Testing on the arcsine 
scale and reporting on the risk-ratio scale is not recommended as it leads to reporting 
results against large margins or significance levels; 
6. An alternative implementation is via our proposed “conditionally modify margin” 
procedure, which re-assesses the margin after observing the control event risk. The 
trial is still designed and analysed in the usual way, using either a risk difference or a 
risk ratio margin; 
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7. When using the “conditionally modify margin” procedure, an appropriate 
modification threshold can be selected through simulations as here. We will make 
available functions to perform such simulations in the R package dani.  
8. If working on the risk difference scale, type I error rate should be controlled using 
simulations as here to find the appropriate nominal significance level. A conservative 
approach uses the largest level leading to a rate always below the nominal one, 
irrespective of the control event risk; otherwise, one can use simulation results to 
modify the significance level depending on the observed control event risk.  
 
4.3. Conclusions 
Our proposed method of designing non-inferiority trials through defining a non-inferiority 
frontier and possibly modifying the non-inferiority margin accordingly after observing the 
control event risk substantially increases their resilience to inadvertent misjudgments of the 
control group event risk. The only disadvantage of this method is that, when working on the 
risk difference scale, some loss of power is expected, and hence sample size should be 
adjusted accordingly. Explicitly acknowledging before a trial starts that there could be 
differences between observed and expected control event risks forces researchers to focus in 
greater depth on the rationale underpinning their choice of non-inferiority margin, and the 
consequences to the trial if they get these assumptions wrong. We consider that researchers 
following our recommendations while designing non-inferiority trials with a binary primary 
outcome will improve the chance that the trial achieves its aims and will make it resilient to 
unexpected differences in the control event risk. 
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Figure 1: Non-inferiority frontiers: comparison of fixed risk ratio (2), fixed risk difference (5%) and power-
stabilising frontiers. The black solid line corresponds to strict equivalence of the two treatments. 
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Table 1: Design parameters of the different simulation scenarios. NOP and NOQ	represent the expected 
control and active event risk, NRQ the maximum tolerable active event risk and r the allocation ratio,  
Scenario   	  Power 
Base-Case 5% =  10% 1 90% 
Alternative 1 10% =  15% 1 90% 
Alternative 2 5% = NOPS  10% 1 90% 
Alternative 3 5% =  7.5% 1 90% 
Alternative 4 5% =  15% 1 90% 
Alternative 5 5% =  10% 0.5 90% 
Alternative 6 5% =  10% 2 90% 
Alternative 7 5% =  10% 1 80% 
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Figure 2: Type I error (top) and power (bottom) of "do not modify margin" and "modify margin" 
procedures, using the risk difference (left) or risk ratio (right) scale. Data are generated according to the 
base-case scenario of Table 1 for varying values of control event risk.  
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Figure 3: Type I error (top) and power (bottom) of the "conditionally modify margin" procedure, using the 
risk difference (left) or risk ratio (right) scale. Data are generated according to the alternative scenarios of 
Table 1 for varying values of control event risk. 
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Figure 4: Power and type I error of procedure 4 ("Conditionally modify margin with small threshold"), 
with different significance levels. Only presenting the risk difference case, as type I error of the base-
case scenario was below the nominal 2.5% level when working on the risk ratio scale.  
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Figure 5: Power and type I error rate of procedure 4 ("Conditionally modify margin with smallest 
threshold"), either with standard significance level (one-sided α=2.5%) or choosing significance level 
using Figure 4 after observing control event risk NJP	to achieve nominal type I error rate; specifically, in 
this example we use α=1% for NJP < T% and  α=1.5% otherwise. 
 
Additional material: 
Appendix A: Sample size calculation formulas 
= sample size control arm 
= sample size active arm 
= standard normal quantile function 
 = significance level 
 = type-II error 
	 = expected risk in the control arm 
	 = expected risk in the active arm 

 =  = allocation ratio 
 = Non-inferiority margin 
 
Risk difference: 
 = (( −  + ( −  ((0 ∗ ( − 0 + 1 ∗ ( − 1/ (1 − 0 −  	 
 =  ∗  
 
Risk ratio: 
  = (( −  + ( −  (((0/(0"(1/( ∗1(#$%(1/0  
 =  ∗  
 
Arc-sine difference: 
 = (( −  + ( −  (
& + & ('()(*1 − '()(*0 − 	 
 =  ∗  
  
Appendix B: Illustrative design and analysis examples 
In this appendix we provide examples of the design and analysis of hypothetical trials following the 
methods presented in this paper. We compare the results with those from the analysis of a trial 
assuming either a fixed risk difference or risk ratio frontier. For all the examples, design parameters 
are as in the base-case scenario of our simulation study, i.e. 	 = 	 = 5% , - = 10% , power = 
90%, one-sided  = 2.5% and r = 1.  
Design 
As described in the main text, because of the different shapes of the non-inferiority frontier, with 
these same design parameters, the estimated total sample sizes for standard non-inferiority trials 
designed with a fixed risk difference, fixed risk ratio, and fixed arc-sine difference are 800, 1664 and 
1136 respectively. 
To incorporate resilience to unanticipated variation in the control event risk into a design using the 
fixed risk difference scale by conditionally modifying the risk difference margin with a threshold 0 = 
1.25% requires either a data-dependent choice of one-sided alpha at the end of the trial or a more 
conservative upfront lowering of the one-sided alpha to 1%. As α=1.5% is the acceptable significance 
level when the expected and observed control event risk match, sample size is inflated to 903 using 
the first method (13% increase from the standard sample size calculation on the risk difference scale 
α=2.5%), while for the second method this goes up to 990 (23% increase). However, as the margin is 
wrongly modified ~20% of the times using the smallest threshold ε, actual power may be slightly 
lower than the nominal level. Future work will explore how to perform a more precise sample size 
calculation.  
Analysis 
For simplicity, we use the same dataset for all analysis methods; although some designs require 
different sample sizes as above, here we illustrate the methods using the sample size required to 
reach 90% power to prove non-inferiority on the arc-sine difference scale within	asin5*-6 −
	asin5*	6	 = 	0.096, , i.e. 568 patients per arm, total 1136 patients. 
We show how to analyse a trial with each of the following methods: 
- Test and report on the arc-sine scale, as in Section 3.1; 
- Test on the arc-sine scale, report on the risk difference scale changing the margin, as in Section 
3.2(i); 
- Test on the arc-sine scale, report on the risk difference scale changing significance level and 
modifying the margin, as in Section 3.2(ii); 
- Test and report on the risk difference scale, as per a standard non-inferiority trial; 
- Test on the risk difference scale, modifying the margin if |: − 	| > 1.25% and testing with 
 = 1%, as in Section 3.5(i).  
- Test on the risk difference scale, modifying the margin if |: − 	| > 1.25% and choosing   using 
Figure (4), as in Section 3.5(ii).  
- Test and report on the risk ratio scale, as per a standard non-inferiority trial on this scale; 
- Test on the risk ratio scale, modifying the margin if |log	(:/	| > log	(1.25 and testing with 
 = 2.5%, as in Section 3.4.  
 
(i) Example 1: actual control and intervention event risks are higher than anticipated 
First we consider the analysis of a trial where the observed event risks in the control and active arms 
are 5% higher than 	 and 	 respectively, i.e. : = 10%	, : = 10%. In our hypothetical example 
trial, we observe 57 events in both the control(: = 10% and active arm (: = 15%. 
Test and report on the arc-sine scale. The estimated arc-sine difference and associated standard 
error are: 
@AB = asin5*:6 −	asin5*:6	 = 	0.000																				C:DE = F 14 + 14 = 0.030 
Hence, the Z statistic is: 
IDE =	@AB − DEC:DE = 	−3.244 
So, the p-value for the test of non-inferiority within margin 0.096 gives a p-value = (IDE < 0.01, 
providing evidence that the new treatment is non-inferior. The two-sided 95% confidence interval 
for the arc-sine difference is: [-0.058; 0.058]. 
Test on the arc-sine scale, report on the risk difference scale changing the margin. Since the test is 
performed on the arc-sine scale, and the trial has been designed on this scale, the Z statistic and p-
value are the same as above. The only difference is that we report the results on the risk difference 
scale by calculating the non-inferiority margin leading to the same Z statistic. Following Section 
3.2(i), we first estimate the risk difference and its associated standard error: 
KLB =	: − : = 0.0%													C:MN = F:(1 − : + :
(1 − : = 1.8%	 
And then we find for which non-inferiority margin MN  these lead to the same Z statistic as IDE: 
MN = KLB − IDE ∗ C:MN = 	5.8% 
Hence, we report that we found the new treatment was non-inferior within the 5.8% risk difference 
margin, with p<0.01 and two-sided 95% confidence interval [-3.5%; 3.5%]. 
Test on the arc-sine scale, report on the risk difference scale changing significance level. Here, the 
estimated risk difference and associated standard error are the same as for the previous method. 
However, the non-inferiority margin is back-calculated from the power-stabilising frontier as: 
MN∗ = PQ(RPQ(*: + RPQ(*- − RPQ(*	S − : = 6.5% 
The Z statistic with this larger non-inferiority margin is: 
IMN = KLB − MN∗C:MN = −− 3.639 
Hence, the ratio between IMN and IDE is equal to 1.12, and TU∗ = 1.11TU = 2.20.	 This is true 
for one-sided ∗ = 1.4%.  
In conclusion, we proved non-inferiority within the 6.5% risk difference margin at the 1.5% one-
sided significance level (p<0.01), with 97.2% two-sided confidence interval [-3.9%; 3.9%]. 
Test and report on risk difference scale. This is a standard non-inferiority trial assuming a fixed risk 
difference frontier. Although an improved method would be preferable here to perform the test due 
to better efficiency
1
, we retain the simple test using normal theory, for simplicity and comparability 
with the other methods. The estimated risk difference and associated standard error are the same as 
with the previous methods, i.e. KLB = 0.0% and C:MN = 1.8%. However, here we test at the pre-
defined 5% non-inferiority margin: 
IDE =	KLB − MNC:MN = 	−2.778																						W < 0.01 
Finally, we report the 95% confidence interval for the risk difference, i.e. [-3.5%; 3.5%], and conclude 
that we provided evidence of non-inferiority at the 5% risk difference margin (p=0.50).  
Test on the risk difference scale with α=1%, modifying the margin. Here, we start again from the 
same estimates of risk difference and associated standard error:  
KLB = 0.0%				C:MN = 1.8%	 
In this example, since |: − 	| = 5% > 1.25%, we modify the margin from the initially intended 
5% to the one back calculated from the arc-sine frontier given :, i.e. 6.5%. Hence, the Z statistic and 
p-value are: 
IMN =	KLB − MN∗C:MN = 	−3.639																						W < 0.01 
In conclusion, we  prove non-inferiority at one-sided 2.5% significance level within the 6.5% margin 
(p<0.01), and the two-sided 95% confidence interval for the risk difference is [-4.2%; 4.2%], larger 
than with the fixed risk difference example as we have used α=1% in order to control type 1 error. 
Test on the risk difference scale, modifying the margin and choosing  α using Figure 4. This method 
is similar to the previous one, but this time the significance level for testing is chosen from Figure 4, 
given that : = 10%. In this specific case, this leads to using a one-sided α=1.5%, and hence the 
confidence interval is now [-3.9%; 3.9%].  
Test and report on the risk ratio scale. The estimated log-risk ratio and associated confidence 
interval are: 
KKB = log	(: − log	(: = 0.00				C:MM = F(1 − :: +
(1 − :: = 0.18 
The non-inferiority margin on the log-risk ratio scale is MM = log X ..YZ = 0.69, leading to the 
following Z statistic for the test on the log-risk ratio scale: 
IMM =	KKB − MMC:MM =	−4.29																						W < 0.01 
There is therefore strong evidence at the one-sided 2.5% significance level that the new treatment is 
non-inferior to the control within a log-risk ratio margin of 0.69, i.e. that the relative risk is less than 
2. Note that since we are working with a fixed risk ratio scale, and : = 10%, we would now be 
happy to tolerate up to : = 20%. In this case the 95% confidence interval should be reported on 
the risk ratio scale: [0.71, 1.42]. 
Test and report on the risk ratio scale, modifying the margin. Since |log	(:/	| = log	(2 >
log	(1.25, the margin is modified according to the power-stabilising frontier: 
MM∗ = log	(PQ(RPQ(*: + RPQ(*- − RPQ(*	S − log	(: = 0.50 
The estimated log-risk ratio and standard error are as before:  
KKB = 0.00				C:MM = 0.18 
Differently from the risk difference case, in this situation there is no need to adjust for type-1 error 
rate, and hence we can keep one-sided α=2.5% as significance level. The Z statistic and p-value are: 
IMM =	KKB − MM∗C:MM =	−3.11																						W < 0.01 
The 95% confidence interval on the risk ratio scale is [0.71; 1.42], and the p-value for the non-
inferiority test within the .Y = 1.65 margin is < 0.01.  
(ii) Other examples. Table (a) below shows the results of the analysis performed on the previous 
example and on two additional examples. These are all based on the same design parameters, i.e. 
those for the base-case scenario of our simulation study, leading to a sample size of 568 patients per 
arm. However, in the second example : = 15%, so that the observed active and control event risk 
differ by 5%, while in the third example : = 6%	, : = 10%, so that the active event risk is close to 
its expected value at the design stage, and hence we do not modify the margin when using methods 
from Section 3.4 and 3.5.  
  
 Table (a): Results of analysis of hypothetical trials using methods presented in this paper and standard 
non-inferiority designs on either the risk difference or risk ratio scales. For each method and example, 
we provide confidence level and corresponding interval, Non-inferiority margin, 1-sided significance level 
for testing and p-value. When using the “Modify Margin” methods, the 1-sided significance level used for 
testing can be modified without this affecting confidence level; this is because a different α is used only 
to maintain type-1 error below the nominal 2.5%, and hence the relevant confidence level is still two-
sided 95%.  
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Method 
CI 
Level 
CI Margin 
1-sided 
α level 
p 
Example 1: : = 10%	, : = 10%      
Test&Report on Arc-sine scale 95% [-0.058; 0.058] 0.096 2.5% <0.01 
Test arc-sine, report RD (change margin) 95% [-3.5%; 3.5%] 5.7% 2.5% <0.01 
Test arc-sine, report RD (change α) 97.2% [-3.9%; 3.9%] 6.5% 1.4% <0.01 
Test RD 95% [-3.5%; 3.5%] 5% 2.5% <0.01 
Test RD, Modify Margin, α=1% 95% [-4.2%; 4.2%] 6.5% 1% <0.01 
Test RD, Modify Margin, choose α 95% [-3.9%; 3.9%] 6.5% 1.5% <0.01 
Test RR 95% [0.71, 1.42] 2 2.5% <0.01 
Test RR, Modify Margin 95% [0.71, 1.42] 1.65 2.5% <0.01 
Example 2: : = 10%	, : = 15%      
Test&Report on Arc-sine scale 95% [0.018; 0.134] 0.096 2.5% 0.25 
Test arc-sine, report RD (change margin) 95% [1.2%; 8.8%] 6.3% 2.5% 0.25 
Test arc-sine, report RD (change α) 97.0% [0.8%; 9.2%] 6.5% 1.5% 0.25 
Test RD 95% [1.2%; 8.8%] 5% 2.5% 0.50 
Test RD, Modify Margin, α=1% 95% [0.3%; 9.7%] 6.5% 1% 0.25 
Test RD, Modify Margin, choose α 95% [0.8%; 9.2%] 6.5% 1.5% 0.25 
Test RR 95% [1.10, 2.06] 2 2.5% 0.04 
Test RR, Modify Margin 95% [1.10; 2.06] 1.65 2.5% 0.29 
Example 3: : = 6%	, : = 10%      
Test&Report on Arc-sine scale 95% [0.016; 0.132] 0.096 2.5% 0.23 
Test arc-sine, report RD (change margin) 95% [0.9%; 7.2%] 5.2% 2.5% 0.23 
Test arc-sine, report RD (change α) 97.4% [0.4%; 7.6%] 5.4% 1.3% 0.23 
Test RD 95% [0.9%; 7.2%] 5% 2.5% 0.27 
Test RD, Modify Margin, α=1% 95% [0.2%; 7.7%] 5% 1% 0.27 
Test RD, Modify Margin, choose α 95% [0.5%; 7.5%] 5% 1.5% 0.27 
Test RR 95% [1.11, 2.51] 2 2.5% 0.20 
Test RR, Modify Margin 95% [1.11; 2.51] 2 2.5% 0.20 
  
Figure (a): total sample size (2 groups) to achieve 90% power for varying control event risks using non-
inferiority margins defined on the risk difference (left panel) and risk ratio (right) scales (two-sided 
alpha=0.05). 
 
Figure (b): power for given sample size for varying control event risks using non-inferiority margins 
defined on the risk difference (N=400, left panel) and risk ratio (N=832, right panel) scales (two-sided 
alpha=0.05) 
 
 Figure (c): Proportion of margins modified using the three different "Conditionally modify margin" 
procedures. Data are generated according to the base-case  scenario of Table 1 for testing type I error 
rate. 
 
 Figure (d): Type I error (top) and power (bottom) of procedure 3 ("Conditionally modify margin with 
medium threshold"), using the risk difference (left) or risk ratio (right) scale. Data are generated 
according to the alternative scenarios of Table 1 for varying values of control event risk. 
 
 Figure (e): Type I error (top) and power (bottom) of procedure 2 ("Conditionally modify margin with 
largest threshold"), using the risk difference (left) or risk ratio (right) scale. Data are generated according 
to the alternative scenarios of Table 1 for varying values of control event risk. 
 
 
